Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Status:
Completed
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03
ophthalmic solution in comparison to a saline control for the treatment of the signs and
symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).